Pelcitoclax (APG-1252) 是一种有效的 Bcl-2/Bcl-xl 抑制剂,具有抗肿瘤和促凋亡作用。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects[1].
APG-1252 changes to the reactive metabolite named APG-1252-M1, which has remarkable antitumor effects in acute myeloid leukemia[1].
Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10days) treatment inhibits xenograft tumor growth more obviously than the other groups[1].
[1]. Hanjie Yi, et al. Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
没有评价数据